You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for FPS ZM1
FPS ZM1 is a high affinity antagonist of the receptor for advanced glycation end products (RAGE) (Ki = 25 nM). Blocks Aβ binding to the V domain of RAGE and inhibits Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. Blocks β-secretase activity, Aβ production, microglia activation and neuroinflammation in vivo. BBB permeable.
Compound Libraries for FPS ZM1
Technical Data for FPS ZM1
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for FPS ZM1
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for FPS ZM1
The following data is based on the product molecular weight 327.85. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.05 mL||15.25 mL||30.5 mL|
|5 mM||0.61 mL||3.05 mL||6.1 mL|
|10 mM||0.31 mL||1.53 mL||3.05 mL|
|50 mM||0.06 mL||0.31 mL||0.61 mL|
References for FPS ZM1
References are publications that support the biological activity of the product.
Deane et al (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta -mediated brain disorder in a mouse model of Alzheimer disease. J.Clin.Invest. 122 1377 PMID: 22406537
Hong et al (2016) Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-beta Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus. Neurochem.Res. 41 1192 PMID: 26738988
If you know of a relevant reference for FPS ZM1, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: FPS ZM1, FPS ZM1 supplier, FPSZM1, Inhibitors, Inhibits, Antagonist, RAGE, Receptor, for, advanced, glycation, end, products, RAP, antagonist, peptide, blood-brain, barrier, BBB, permeable, penetrant, AB42, Aβ, Aβ42, Alzheimer's, Disease, NF-kB/IkB, 6237, Tocris Bioscience
3 Citations for FPS ZM1
Citations are publications that use Tocris products. Selected citations for FPS ZM1 include:
Hui et al (2021) Proof-of-concept study investigating the role of S100P-RAGE in nasopharyngeal carcinoma. Exp Ther Med 21 470 PMID: 33767765
Venkat et al (2021) S100B Inhibition Attenuates Intestinal Damage and Diarrhea Severity During Clostridioides difficile Infection by Modulating Inflammatory Response. Front Cell Infect Microbiol 11 739874 PMID: 34568098
Uderhardt et al (2019) Resident Macrophages Cloak Tissue Microlesions to Prevent Neutrophil-Driven Inflammatory Damage. Cell 177 541 PMID: 30955887
Do you know of a great paper that uses FPS ZM1 from Tocris? Please let us know.
Reviews for FPS ZM1
Average Rating: 5 (Based on 1 Review.)
Have you used FPS ZM1?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
DMSO dilution 10 μM
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.